Literature DB >> 3490446

Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.

J F Cajot, E K Kruithof, W D Schleuning, B Sordat, F Bachmann.   

Abstract

We have analyzed the CM of 20 human tumor cell lines for the presence of PA, PA-I and PC. Most of the cell lines expressed PA activity as measured by a radioiodinated fibrin plate assay. The urinary type and tissue-type PA activities were specifically quantified by means of purified inhibitory antibodies. U-PA and/or t-PA antigen, as measured by radioimmunoassays, were detected in all but 4 of the CM and were generally 10 times more concentrated than PA activity, indicating the presence of specific PA-Is. Analysis of CM by electrophoresis followed by fibrin-agarose zymography demonstrated the presence not only of free but also of inhibitor-complexed PA. Affinity purification demonstrated that 8/20 cell lines expressed detectable PA-I activity. The PA-I1 and PA-I2 inhibitors were most frequently observed, while PN was recovered only from CM of the HT1080 fibrosarcoma cell line. PC activity, as measured by the plasma recalcification time method, was found in 9/20 CM. It was of the thromboplastin tissue factor type since most of its activity was lost when assayed with a Factor VII-deficient plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490446     DOI: 10.1002/ijc.2910380516

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  The status of trypsin-like enzymes in squamous-cell carcinoma of the head and neck region.

Authors:  F S Steven; L A Williams; H Maier; J Arndt; H Weidauer; A Born
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent.

Authors:  M Szczepański; K Bardadin; J Zawadzki; W Pypno
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

5.  Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.

Authors:  Attalla Farag El-Kott; Abdalla Mohamed Khalil; Ayman El-Meghawry El-Kenawy
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

Authors:  J F Cajot; J Bamat; G E Bergonzelli; E K Kruithof; R L Medcalf; J Testuz; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L T Kirkeby; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

8.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

9.  Differential protease expression by cutaneous squamous and basal cell carcinomas.

Authors:  A P Sappino; D Belin; J Huarte; S Hirschel-Scholz; J H Saurat; J D Vassalli
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

10.  Secretion of plasminogen activators by human colorectal and gastric tumor explants.

Authors:  S R Harvey; D D Lawrence; J M Madeja; S J Abbey; G Markus
Journal:  Clin Exp Metastasis       Date:  1988 Nov-Dec       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.